Fumika Nakamura1, Yasushi Sato1, Koichi Okamoto1, Yasuteru Fujino1, Yasuhiro Mitsui1, Kaizo Kagemoto1, Tomoyuki Kawaguchi1, Hiroshi Miyamoto1, Naoki Muguruma1, Tomoko Sonoda2, Koichi Tsuneyama3, Tetsuji Takayama4. 1. Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. 2. Department of Public Health, Sapporo Medical University School of Medicine, Minami 1-jo Nishi 17-chome, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan. 3. Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. 4. Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan. takayama@tokushima-u.ac.jp.
Abstract
BACKGROUND: Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. METHODS: We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. RESULTS: Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. CONCLUSIONS: Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis.
BACKGROUND: Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. METHODS: We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. RESULTS: Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. CONCLUSIONS: Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis.
Authors: Daniel D Buchanan; Mark Clendenning; Li Zhuoer; Jenna R Stewart; Sharelle Joseland; Sonja Woodall; Julie Arnold; Kara Semotiuk; Melyssa Aronson; Spring Holter; Steven Gallinger; Mark A Jenkins; Kevin Sweet; Finlay A Macrae; Ingrid M Winship; Susan Parry; Christophe Rosty Journal: Gut Date: 2016-08-31 Impact factor: 23.059
Authors: Isabel Quintana; Raquel Mejías-Luque; Mariona Terradas; Matilde Navarro; Virginia Piñol; Pilar Mur; Sami Belhadj; Elia Grau; Esther Darder; Ares Solanes; Joan Brunet; Gabriel Capellá; Markus Gerhard; Laura Valle Journal: Gut Date: 2018-01-12 Impact factor: 23.059
Authors: B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos Journal: N Engl J Med Date: 1988-09-01 Impact factor: 91.245
Authors: Christophe Rosty; Daniel D Buchanan; Michael D Walsh; Sally-Ann Pearson; Erika Pavluk; Rhiannon J Walters; Mark Clendenning; Kevin J Spring; Mark A Jenkins; Aung K Win; John L Hopper; Kevin Sweet; Wendy L Frankel; Melyssa Aronson; Steve Gallinger; Jack Goldblatt; Sonja Woodall; Julie Arnold; Neal I Walker; Jeremy R Jass; Susan Parry; Joanne P Young Journal: Am J Surg Pathol Date: 2012-06 Impact factor: 6.394
Authors: Karam S Boparai; Elisabeth M H Mathus-Vliegen; Jan J Koornstra; Fokko M Nagengast; Monique van Leerdam; Carel J M van Noesel; Martin Houben; Annemieke Cats; Liselotte P van Hest; Paul Fockens; Evelien Dekker Journal: Gut Date: 2009-08-25 Impact factor: 23.059
Authors: Sabela Carballal; Daniel Rodríguez-Alcalde; Leticia Moreira; Luis Hernández; Lorena Rodríguez; Francisco Rodríguez-Moranta; Victoria Gonzalo; Luis Bujanda; Xavier Bessa; Carmen Poves; Joaquin Cubiella; Inés Castro; Mariano González; Eloísa Moya; Susana Oquiñena; Joan Clofent; Enrique Quintero; Pilar Esteban; Virginia Piñol; Francisco Javier Fernández; Rodrigo Jover; Lucía Cid; María López-Cerón; Miriam Cuatrecasas; Jorge López-Vicente; Maria Liz Leoz; Liseth Rivero-Sánchez; Antoni Castells; María Pellisé; Francesc Balaguer Journal: Gut Date: 2015-08-11 Impact factor: 23.059
Authors: J E G IJspeert; S A Q Rana; N S S Atkinson; Y J van Herwaarden; B A J Bastiaansen; M E van Leerdam; S Sanduleanu; T M Bisseling; M C W Spaander; S K Clark; G A Meijer; N van Lelyveld; J J Koornstra; I D Nagtegaal; J E East; A Latchford; E Dekker Journal: Gut Date: 2015-11-24 Impact factor: 23.059
Authors: Francesc Balaguer; Evelien Dekker; Arne Gc Bleijenberg; Joep Eg IJspeert; Yasmijn J van Herwaarden; Sabela Carballal; María Pellisé; Gerhard Jung; Tanya M Bisseling; Iris D Nagetaal; Monique E van Leerdam; Niels van Lelyveld; Xavier Bessa; Francisco Rodríguez-Moranta; Barbara Bastiaansen; Willemijn de Klaver; Liseth Rivero; Manon Cw Spaander; Jan Jacob Koornstra; Luis Bujanda Journal: Gut Date: 2019-04-13 Impact factor: 23.059
Authors: Christophe Rosty; David G Hewett; Ian S Brown; Barbara A Leggett; Vicki L J Whitehall Journal: J Gastroenterol Date: 2012-12-04 Impact factor: 7.527